<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180602039951N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-15</date_registration>
      <primary_sponsor>Dental School of Kerman University of Medical science</primary_sponsor>
      <public_title>Evaluation of therapeutic effect and placebo effect of low level laser therapy in temporomandibular disorders</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of therapeutic effect and placebo effect of low level laser therapy in temporomandibular disorders</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/36721</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: randomization will be done by computer software, patients will be divided to 3 groups, receptionist  will extract patient's group and pass it to operator in sealed envelop. patients and doctors that evaluate treatment result will not be informed of patient's groups, Blinding description: patients: Blind 
interviewer:  Blind
therapist: Blind
low level leaser machine operator:  informed 
receptionist will extract patient's group and pass it to operator in sealed envelop. patients and their doctors will not informed. patients are blindfolded and beeping sound of machine is on for both groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>temporomandibular disorders.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: gallium–aluminum–arsenide,  808nm ، 300 mw، 3J/cm2 ،  10S 10 session ( twice a week for 5 weeks), 4 points around temporomandibular joint and every muscle trigger point in head and neck. Intervention 2: Intervention group: Intervention group 2 : using the same device that used in intervention group 1. Intervention in this group will be same as intervention group except that the device will be in active. Intervention 3: Control group: patients in this group will not face low level leaser therapy and will follow standard treatment protocol.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
all collected deidentified IPD, IPD collected for the primary outcome measure only

When:
6 months after publication

To whom:
for people working in academic institutions or people working in businesses

Conditions:
people working in academic institutions

Where to obtain:
s.mafi@kmu.ac.ir 
Dr.Sahar Mafi

How to obtain:
requests containing how the data will be used must be applied via Email.  Citation in future publication is mandatory. Data will be sent within 3 months.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sahar Mafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shafa Boulevard, Kerman, Kerman Province</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618759689</zip>
        <telephone>+98 34 3211 9021</telephone>
        <email>s.mafi@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sahar Mafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jomhouri Boulevard, Shafa Boulevard, Kerman Province, Kerman,</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618759689</zip>
        <telephone>+98 34 3211 8074</telephone>
        <email>s.mafi@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>acute and chronic myofascial pain ( muscle trigger point)
TMJ tenderness without degenerative diseases
limitation of mouth opening due to muscle pain or TMJ inflammation
ability of reading and writing to answer questionnaires
patient cooperation and compliance
men and women between 15-60 years old</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>using NSAID, corticosteroids,anti-convulsant, anti-psychotic,  anti-depressant and narcotics
mixed dentition
developmental  head and face deformity
current orthodontic treatment, orthopedic appliance or splint therapy
dental carries which replicated patient's pain in head and face
partial or complete denture
pregnancy and breast feeding
history of pathological lesions in temporomandibular regions
history of chemotherapy and radiotherapy of head and neck
inability of answer to questionnaires
periodontal diseases
rheumatologic diseases
Degenerative Joint Disease TMJ</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M26.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Temporomandibular joint disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: gallium–aluminum–arsenide,  808nm ، 300 mw، 3J/cm2 ،  10S 10 session ( twice a week for 5 weeks), 4 points around temporomandibular joint and every muscle trigger point in head and neck.</i_keyword>
      <i_keyword>Intervention group: Intervention group 2 : using the same device that used in intervention group 1. Intervention in this group will be same as intervention group except that the device will be in active.</i_keyword>
      <i_keyword>Control group: patients in this group will not face low level leaser therapy and will follow standard treatment protocol.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Effect of low level leaser therapy on total trigger point score. Timepoint: Total trigger point score before intervention, and 1, 2, 3,4,5,weeks during intervention and one month  after final intervention will be recorded. Method of measurement: head and neck muscles examination.</prim_outcome>
      <prim_outcome>Effect of low level leaser therapy on jaw sounds. Timepoint: before intervention, and 1, 2, 3,4,5,weeks during intervention. Method of measurement: Stethoscope.</prim_outcome>
      <prim_outcome>Effect of low level leaser therapy on jaw movement. Timepoint: before intervention, and 1, 2, 3,4,5,weeks during intervention. Method of measurement: ruler.</prim_outcome>
      <prim_outcome>Effect of low level leaser therapy on visual analog scale. Timepoint: before intervention, and 1, 2, 3,4,5,weeks during intervention. Method of measurement: visual analog scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dental School of Kerman University of Medical science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-03-12</approval_date>
        <contact_name>ethics committee of Kerman university of medical science</contact_name>
        <contact_address>Kerman University of Medical Sciences,Medical University Campus,Haft-Bagh Highway, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
